Rochester General Hospital-Lab

Rochester General Hospital-Lab was paid $33.28M by Medicaid between Jan 2018 and Dec 2024, across 268 billing codes. Its largest line is U0004, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r — 15% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in New York

Rank by total paid#11 of 116

Median peer was paid$618K

This provider vs. median54×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	89	$22K
2019	3,410	$134K
2020	13,067	$535K
2021	432,110	$9.46M
2022	434,528	$9.40M
2023	416,607	$7.63M
2024incomplete	353,776	$6.10M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	15%	66,405	64,270	$4.94M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	7.1%	48,291	34,757	$2.36M
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	5.9%	62,455	60,210	$1.97M
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	5.9%	62,434	60,208	$1.96M
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	4.7%	62,709	60,793	$1.55M
88305	Level IV - Surgical pathology, gross and microscopic examination	4.6%	11,171	10,092	$1.53M
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	4.0%	17,651	17,500	$1.32M
84443	Thyroid stimulating hormone (TSH)	3.2%	72,067	71,360	$1.05M
80053	Comprehensive metabolic panel	2.4%	88,467	86,095	$814K
87480		2.4%	45,386	43,875	$798K
87510		2.4%	44,607	43,140	$784K
87660		2.4%	44,560	43,094	$783K

256 more codes

82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	2.3%	30,586	$773K
88142		2.3%	28,796	$772K
87631		2.3%	6,925	$763K
80061	Lipid panel	2.3%	64,999	$757K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	1.6%	29,173	$546K
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	1.6%	17,743	$529K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	1.4%	68,465	$461K
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	1.2%	9,390	$394K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	1.1%	12,410	$371K
86780		<1%	28,222	$332K
87086	Culture, bacterial; quantitative colony count, urine	<1%	40,597	$287K
83036	Hemoglobin; glycosylated (A1C)	<1%	32,651	$273K
82607		<1%	21,161	$270K
86481		<1%	4,202	$226K
85027		<1%	39,340	$222K
86803		<1%	15,956	$199K
86480		<1%	3,244	$173K
84439		<1%	21,863	$172K
80048	Basic metabolic panel (calcium, ionized)	<1%	24,569	$171K
87634		<1%	3,123	$169K
82728		<1%	13,237	$157K
87081		<1%	26,400	$154K
83970		<1%	4,223	$151K
88342		<1%	1,321	$145K
87506		<1%	739	$134K
84702		<1%	9,944	$132K
88304		<1%	1,727	$115K
84403		<1%	4,825	$109K
87340		<1%	11,518	$104K
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	<1%	1,140	$97K
82746		<1%	8,164	$96K
83550		<1%	11,899	$90K
88112		<1%	876	$84K
G0103	Prostate cancer screening; prostate specific antigen test (psa)	<1%	5,281	$84K
87186		<1%	10,694	$82K
87505		<1%	749	$81K
83655		<1%	7,423	$79K
87070		<1%	9,727	$74K
83540		<1%	12,852	$72K
83013		<1%	1,175	$69K
84402		<1%	3,119	$69K
86706		<1%	7,047	$66K
82670		<1%	2,660	$65K
86003		<1%	1,776	$64K
86038		<1%	6,052	$64K
83001		<1%	3,901	$64K
86762		<1%	7,369	$61K
83880		<1%	2,193	$60K
86235		<1%	2,491	$60K
82570		<1%	15,651	$60K
87077		<1%	7,537	$59K
80076		<1%	8,391	$59K
84146		<1%	3,407	$58K
82043		<1%	11,545	$57K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	2,082	$56K
83735		<1%	9,155	$53K
86696		<1%	3,100	$52K
84207		<1%	2,101	$51K
87088		<1%	6,959	$51K
81001		<1%	17,844	$49K
84425		<1%	2,626	$48K
84480		<1%	3,873	$48K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	1,215	$48K
86140		<1%	12,955	$43K
86704		<1%	3,949	$42K
87536		<1%	557	$41K
87147		<1%	8,767	$40K
83520		<1%	3,406	$40K
82784		<1%	3,406	$38K
86850		<1%	5,923	$38K
86160		<1%	2,451	$38K
85652		<1%	15,894	$37K
83002		<1%	2,287	$37K
87522	Neg quan hep c or qual rna	<1%	977	$36K
88312		<1%	250	$36K
81420	Fetal chromosomal aneuploidy genomic sequence analysis panel	<1%	69	$35K
81508		<1%	997	$34K
87150		<1%	1,040	$32K
85610		<1%	8,836	$30K
87529		<1%	946	$30K
82533		<1%	1,883	$28K
86376		<1%	2,214	$28K
82105		<1%	1,941	$28K
86141		<1%	2,418	$27K
86787		<1%	3,255	$27K
84153		<1%	1,656	$26K
86225		<1%	2,143	$26K
84144		<1%	1,414	$26K
86200		<1%	2,261	$26K
81511		<1%	264	$25K
84255		<1%	1,096	$25K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	484	$24K
82525		<1%	2,221	$24K
83690		<1%	4,203	$24K
86765		<1%	2,826	$23K
82627		<1%	1,119	$22K
88341		<1%	120	$21K
86735		<1%	2,545	$21K
86431		<1%	4,182	$21K
80069		<1%	2,775	$21K
86708		<1%	1,874	$20K
84446		<1%	1,631	$20K
86618		<1%	2,333	$20K
83516		<1%	1,586	$20K
84681		<1%	1,082	$20K
87338		<1%	1,553	$20K
84630		<1%	2,259	$19K
83993		<1%	1,160	$19K
87252		<1%	846	$19K
84590		<1%	1,872	$19K
84597		<1%	1,576	$19K
83020		<1%	1,657	$19K
86364		<1%	2,546	$18K
82950		<1%	4,515	$17K
86695		<1%	2,125	$17K
86665		<1%	1,362	$16K
86800		<1%	1,485	$16K
86901		<1%	6,097	$16K
86900		<1%	6,066	$16K
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	497	$15K
83921		<1%	1,067	$15K
82785		<1%	1,046	$15K
G0328	Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous	<1%	1,384	$15K
84481		<1%	1,008	$15K
84550		<1%	3,804	$15K
84156		<1%	4,584	$15K
84703		<1%	2,159	$14K
83525		<1%	1,403	$14K
82150		<1%	2,471	$14K
82550		<1%	2,385	$14K
83721		<1%	1,632	$13K
87272		<1%	1,278	$13K
85730		<1%	2,390	$13K
84460		<1%	2,715	$12K
86039		<1%	1,219	$12K
80074		<1%	290	$12K
83615		<1%	2,075	$11K
88184		<1%	150	$11K
84450		<1%	2,352	$11K
84165		<1%	1,135	$11K
81003		<1%	5,303	$10K
86360		<1%	254	$10K
82248		<1%	2,331	$10K
87102		<1%	1,280	$10K
83090		<1%	670	$10K
87255		<1%	330	$10K
86147		<1%	560	$10K
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	<1%	96	$10K
87449		<1%	867	$9K
82565		<1%	1,898	$8K
87253		<1%	546	$8K
83014		<1%	1,190	$8K
84100		<1%	1,911	$8K
82951		<1%	775	$8K
82977		<1%	1,252	$8K
80050	General health panel	<1%	268	$7K
82465		<1%	1,828	$7K
82947		<1%	2,020	$7K
85014		<1%	3,330	$7K
83498		<1%	287	$7K
87269		<1%	666	$7K
86146		<1%	388	$7K
84163		<1%	500	$7K
87209		<1%	374	$6K
83021		<1%	394	$6K
84478		<1%	1,209	$6K
82247		<1%	1,313	$6K
85018		<1%	2,672	$6K
86359		<1%	167	$5K
99001		<1%	752	$5K
80164		<1%	440	$5K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	<1%	69	$5K
80178		<1%	851	$5K
81025		<1%	797	$4K
87493		<1%	142	$4K
84152		<1%	273	$4K
85045		<1%	1,136	$4K
85379		<1%	443	$4K
84445		<1%	148	$4K
86308		<1%	800	$4K
P9604	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge	<1%	355	$3K
82330		<1%	285	$3K
87101		<1%	489	$3K
87324		<1%	332	$3K
85613		<1%	385	$3K
82310		<1%	717	$3K
82088		<1%	88	$3K
82103		<1%	267	$3K
82390		<1%	358	$3K
84466		<1%	262	$3K
82952		<1%	777	$3K
86015		<1%	377	$3K
85240		<1%	163	$3K
85246		<1%	118	$2K
85245		<1%	118	$2K
86317		<1%	26	$2K
84155		<1%	686	$2K
82677		<1%	112	$2K
87106		<1%	336	$2K
87177		<1%	234	$2K
87641		<1%	60	$2K
84436		<1%	301	$2K
85049		<1%	459	$2K
86336		<1%	125	$2K
86334		<1%	87	$2K
86705		<1%	163	$2K
83630		<1%	97	$2K
84132		<1%	394	$2K
86036		<1%	190	$1K
82166		<1%	56	$1K
84520		<1%	383	$1K
84075		<1%	281	$1K
82040		<1%	283	$1K
84244		<1%	62	$1K
86617		<1%	78	$1K
82653		<1%	65	$935.35
86255		<1%	84	$913.32
87075		<1%	115	$861.47
83695		<1%	76	$855.75
86709		<1%	87	$841.20
86304		<1%	44	$806.96
87205		<1%	240	$656.90
87206		<1%	126	$652.74
82378		<1%	42	$640.18
81050		<1%	242	$632.80
84295		<1%	142	$593.60
83835		<1%	38	$582.27
86694		<1%	68	$565.76
83521		<1%	52	$562.64
84305		<1%	31	$499.10
87517		<1%	13	$490.75
82374		<1%	106	$448.24
84432		<1%	63	$440.28
82435		<1%	107	$425.25
84134		<1%	27	$334.10
0077U		<1%	12	$326.40
86060		<1%	53	$321.18
82272		<1%	109	$312.83
86305		<1%	16	$293.44
80051		<1%	50	$281.50
87140		<1%	50	$255.32
87040		<1%	27	$254.80
84270		<1%	13	$248.95
86592		<1%	92	$233.68
86645		<1%	27	$232.47
83789		<1%	12	$190.92
84166		<1%	14	$179.34
87107		<1%	27	$173.44
80306		<1%	12	$153.72
82610		<1%	13	$130.13
86644		<1%	12	$99.84
85384		<1%	12	$89.76
80047		<1%	12	$77.66
82340		<1%	12	$63.84
85660		<1%	12	$58.32
36415	Collection of venous blood by venipuncture	0%	1,173	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialMIDOLO, JOHN (VP FINANCE)

Parent organizationROCHESTER GENERAL HOSPITAL